Supplementary material



Chart S1. Clinically used MRI contrast agents.



Figure 1. HR-FAB mass spectroscopy data of (1) (Top) and (2) (Bottom).







**Figure 3.** <sup>1</sup>H NMR spectroscopy data of (1).



Figure 4. <sup>1</sup>H NMR spectroscopy data of (2).



Figure 5. Peak purity in Prep-HPLC of (1) at 365 nm, (2) and GdL (3) at 330 nm detection.



Figure 6. Absorption (Red) and Emission (Blue) spectra of GdL (3).



**Figure 7.** Biodistribution of **GdL** (**3**) and Gd-BT-DO3A (Gadovist<sup>®</sup>) in various tissues (each group n = 3).



**Figure 8.** Cell viability of immortalized mouse myoblast cell line (C2C12) in various AA, Gd-BT-DO3A, RosA and **GdL (3)** concentrations.

![](_page_6_Figure_2.jpeg)

Figure 9. DCFDA object mean (fluorescence intensity) of PA-induced ROS.

![](_page_7_Figure_0.jpeg)

**Figure 10.** The expression pattern of (A) SOD and (B) COX-2 according to various concentrations (100, 200, 300, and 500  $\mu$ M) of palmitic acid. (*n* = 3 per each).

![](_page_7_Figure_2.jpeg)

**Figure S11.** Expression of COX-2 and TNF- $\alpha$  in mice with turpentine oil injection dose. (A) COX-2 expression level according to turpentine oil injection dose. (B) TNF- $\alpha$  expression level according to turpentine oil injection dose.